From July 5-7, 2024, the "2024 Annual Progress in Clinical Oncology Conference (BOC) and Best of ASCO® 2024 China (BOC/BOA)" was grandly held in Guangzhou. In the field of breast cancer, this conference highlighted key advancements from the American Society of Clinical Oncology (ASCO) annual meeting, showcasing China's research impact on the international stage. "Oncology Frontier" interviewed Dr. Qiang Liu, host of the breast cancer session and from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, to share session highlights and impacts, pointing out future trends in breast cancer treatment development.

On July 12-13, the 2024 CACA Integrated Breast Cancer Conference was held in Kunming, hosted by the Chinese Anti-Cancer Association (CACA) and the CACA Integrated Breast Cancer Committee, and organized by the China Academy of Integrated Medicine and Strategy Development, Yunnan Cancer Hospital, and ten professional committees. "Oncology Frontier" invited Dr. Jiong Wu, Chairman of the conference and from Fudan University Shanghai Cancer Center, to elaborate on the concept of "Winning in Integration for Tumor Prevention and Treatment." He discussed the challenges in breast cancer treatment under the integrated medicine philosophy and shared suggestions for better implementation of integrated breast cancer treatment in primary healthcare institutions.

The "2024 CACA Integrated Breast Cancer Conference," hosted by the Chinese Anti-Cancer Association and the Chinese Anti-Cancer Association's Breast Cancer Committee, was held in Kunming, Yunnan, from July 12-13, 2024. The conference, under the theme "Cancer Prevention and Treatment: Winning Through Integration," focused on new concepts, knowledge, and technologies in breast cancer diagnosis and treatment, discussing strategies for precise and standardized treatment. During the event, the 10th Committee of the Chinese Anti-Cancer Association's Breast Cancer Professional Committee (referred to as the Committee) was elected. Dr. Jin Zhang from Tianjin Medical University Cancer Institute and Hospital was elected as the Chair of the 10th Committee. In an interview, Professor Zhang shared her vision for the future work of the Committee and her insights on integrating breast cancer prevention and treatment efforts.

With the continuous advancement of cancer treatment technologies, the survival rate of cancer patients has significantly improved, but the issue of cardiac safety during antitumor therapy has increasingly become a clinical focus. In this context, cardio-oncology has emerged as an important interdisciplinary field. At the "2024 CACA Integrated Breast Cancer Conference," during the breast cancer integration and rehabilitation session, Dr. Fengqi Fang from The First Affiliated Hospital of Dalian Medical University shared her insights on "Cardiac Safety Management in Antitumor Therapy for Breast Cancer." After the session, "Oncology Frontier" interviewed Professor Fang on the latest research and future directions in cardio-oncology.

At the 2024 ASCO Conference, the progress in breast cancer ADC (antibody-drug conjugate) research was remarkable. T-DXd demonstrated excellent efficacy in HER2-positive breast cancer, significantly extending patient survival and reinforcing the concept of using the best drugs first. In HR-positive and triple-negative breast cancer, Dato-DXd showed good safety and efficacy, laying the foundation for future combination therapy regimens. Additionally, domestic ADC drugs like ARX788 and SKB264 provided new treatment options for breast cancer patients. In this article, Dr. Songqing Ye from Fujian Provincial Hospital provides an in-depth analysis of the latest research findings on ADC drugs in HER2-positive, HR-positive, and triple-negative breast cancer presented at the 2024 ASCO Conference.

Head and neck tumors are common malignant tumors among Chinese residents, significantly impacting organ function, quality of life, and prognosis due to disease progression and treatment effects. The "2024 Annual Progress in Clinical Oncology Conference (BOC) and Best of ASCO 2024 China" was recently held in Guangzhou, showcasing the progress of clinical oncology research in China and sharing cutting-edge information from the ASCO conference. On this occasion, "Oncology Frontier" invited Dr. Ye Guo from Shanghai East Hospital , Tongji University to share key research insights related to head and neck tumors.